<\/p>\n\n\n\n
The drug Tecentriq (atezolizumab) obtained authorization from the National Authority for Medicines and Health Products (Infarmed) to be used in hospitals in new indications for the treatment of lung cancer.<\/p>\n\n\n\n
According to the grant recently published on the Infarmed website, Tecentriq (atezolizumab), in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with large-scale small cell lung cancer (SCLC-ED). It is important to mention that this is the first therapeutic innovation in more than 20 years for these patients.<\/p>\n\n\n\n
Additionally and according to this publicly released note, Tecentriq (Atezolizumab) monotherapy is indicated for the first-line treatment of adult patients with metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumors have a PD-L1 expression of \u2265 50 % of tumor cells (CT) or \u2265 10% of tumor-infiltrating immune cells (CI) that do not have EGFR-mutated or ALK-positive mNSCC.
At the same time, the 840mg ampoule was also financed, which now allows for greater dosage flexibility with Atezolizumab. Tecentriq (Atezolizumab), in combination or monotherapy, can be administered: 1) every 4 weeks – 1680 mg (2 ampoules of 840 mg); 2) every 3 weeks – 1200 mg ampoule; 3) every 2 weeks – 840 mg ampoule.<\/p>\n\n\n\n
Good news for the national panorama in the provision of treatments for patients with lung cancer.<\/p>\n\n\n\n